Sat.Feb 24, 2024 - Fri.Mar 01, 2024

article thumbnail

Vaccine successfully lowers cholesterol in preclinical studies

Drug Discovery World

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. VXX-401 is a synthetic peptide vaccine designed to stimulate the immune system to produce antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), whi

Vaccine 260
article thumbnail

Optimizing OpenFold Training for Drug Discovery

Nvidia Developer: Drug Discovery

Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep. Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep learning–based computational methods have been emerging and have shown promising results.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI outperforms humans in standardized tests of creative potential

Science Daily: Pharmacology News

In a recent study, 151 human participants were pitted against ChatGPT-4 in three tests designed to measure divergent thinking, which is considered to be an indicator of creative thought.

129
129
article thumbnail

Viking data suggest obesity drug could rival Zepbound, Wegovy

BioPharma Drive: Drug Pricing

The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

Drugs 124
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

2023 cancer research highlights: Drug development at its best

Drug Discovery World

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9 million new cancer cases are expected to be diagnosed in the US in 2023”.

article thumbnail

Eye Ointments Sold at Walmart, CVS Recalled Due to Infection Risk

Drugs.com

TUESDAY, Feb. 27, 2024 -- Eye ointment products made in India and sold in the United States at Walmart, CVS and other retailers are being recalled due to a danger of infection.Brassica Pharma Pvt. Ltd., of Maharastra, India, said it is recalling.

More Trending

article thumbnail

Perficient Included in Forrester’s The Adobe Services Landscape

Perficient: Drug Development

In a dynamic digital landscape, choosing the right provider among the Adobe services landscape is paramount for businesses seeking to maximize their Adobe investments. The selection process can be daunting with a diverse set of providers that vary by size, type of offering, geography, and business scenario differentiation. So where do marketing leaders start?

Marketing 115
article thumbnail

Putting human data at the centre of drug discovery

Drug Discovery World

James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In what ways can human data benefit neurology drug discovery? JP: At the end of the day, what matters to patients is all that matters.

Drugs 147
article thumbnail

Drug limits dangerous reactions to allergy-triggering foods, Stanford Medicine-led study of kids finds

Science Daily: Pharmacology News

A drug that binds to allergy-causing antibodies can protect children from dangerous reactions to accidentally eating allergy-triggering foods, a new study found.

Drugs 121
article thumbnail

Treating Crohn's Sooner, More Aggressively Greatly Improves Outcomes: Study

Drugs.com

MONDAY, Feb. 26, 2024 -- In a finding that suggests sooner is better than later, a new trial shows that giving advanced treatment early to Crohn’s patients can dramatically improve their gut health.About 80% of those who got therapy with an.

Therapies 116
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Do You Have An Enterprise Data Strategy?

Perficient: Drug Development

This time of year, I like to talk about updating the data strategy for the new year to include new business goals and new technology and in doing so I sometimes forget that there are still many companies that do not have a data strategy to update. What is a Data Strategy and why do I need one? Most organizations have multiple data management initiatives underway including master data management, data governance, data migration, data modernization, OLTP operational data cleanup, data ingestion, a

article thumbnail

Moving the needle of CAR-T beyond oncology 

Drug Discovery World

CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology making this happen.

DNA 147
article thumbnail

CDC panel mulls changes to RSV vaccine recommendation

BioPharma Drive: Drug Pricing

The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.

Vaccine 114
article thumbnail

CDC Shortens Recommended COVID Isolation Period

Drugs.com

FRIDAY, March 1, 2024 -- New guidance issued Friday by the U.S. Centers for Disease Control and Prevention recommends that Americans who test positive for COVID-19 no longer need to routinely stay home for five days. Instead, the CDC recommends.

Disease 111
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Rare Disease Day: Understanding the power of diagnosis and connection

Antidote

Rare Disease Day, typically observed on February 28th, will be celebrated this year on February 29th! Rare Disease Day is an awareness holiday intended to generate change for the 300 million people who are diagnosed with a rare disease worldwide, as well as their families and caregivers.

Disease 111
article thumbnail

Late-stage drug failures drive toxicology testing market growth

Drug Discovery World

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 billion by 2030, with a growth rate of 10.2%. Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market. The predictions are made by ResearchAndMarkets.com in a new market report entitled ‘ADME Toxicology Testing Market Size, Share & Trends Analysis Repo

Marketing 147
article thumbnail

Significant glacial retreat in West Antarctica began in 1940s

Science Daily: Pharmacology News

Among the vast expanse of Antarctica lies the Thwaites Glacier, the world's widest glacier measuring about 80 miles on the western edge of the continent. Despite its size, the massive landform is losing about 50 billion tons of ice more than it is receiving in snowfall, which places it in a precarious position in respect to its stability. Accelerating ice loss has been observed since the 1970s, but it is unclear when this significant melting initiated -- until now.

111
111
article thumbnail

CDC Experts Recommend Seniors Get Another COVID Shot

Drugs.com

THURSDAY, Feb. 29, 2024 -- Even if they got a COVID booster last fall, American seniors should still get a second shot this spring to best protect themselves, U.S. health officials recommended Wednesday.The latest guidance, voted on by a vaccine.

Vaccine 111
article thumbnail

Women in Stem with Dr Amber D. Van Laar

Drug Target Review

Can you tell us about your journey in the field of STEM and the challenges you encountered along the way? From a very young age, I was drawn to science and medicine. My interest in the field of STEM sharpened when, in my early teens, I had the chance to work in a neuro-oncology lab. This early exposure to bench science had a long-lasting impact. It propelled me to continue lab work during my undergraduate training, my medical training, and to an academic appointment in the Movement Disorders Div

Therapies 111
article thumbnail

This week in drug discovery (26 Feb – 1 March) 

Drug Discovery World

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and the CHMP recommended an extension to the use of Carvykti in melanoma, but there was also bad news for Minerva Biosciences and Oncopeptides.

FDA 130
article thumbnail

#ScienceSaturday: February 24, 2024

KIF1A

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. KIF1A-Related Research A Model for Chemomechanical Coupling of Kinesin‑3 Motor Like humans, KIF1A pairs walk one step at a time, one foot in front of the other.

Disease 111
article thumbnail

Say Goodbye to PFAS Chemicals in Food Packaging: FDA

Drugs.com

WEDNESDAY, Feb. 28, 2024 -- PFAS "forever" chemicals, increasingly linked to health risks, will no longer be added to food packaging handled by American consumers, the U.S. Food and Drug Administration announced Wednesday."Grease-proofing materials.

Packaging 111
article thumbnail

A smartphone app for the self-management of Perthes’ Disease – a blog for Rare Disease Day 2024

On Medicine

What is Perthes’ disease? Perthes’ Disease is a rare condition that affects the developing femoral head (the “ball” of the “ball and socket” hip joint) of a child due to poor blood supply. In this condition, the blood supply to the femoral head is disrupted and this leads to joint deformity. The destruction typically causes the femoral head to flatten and not fit well in the acetabulum (the “socket” of the hip joint).

Disease 109
article thumbnail

Bristol Myers Squibb buys radiopharmaceuticals company for $4 billion

Drug Discovery World

Bristol Myers Squibb has completed its acquisition of RayzeBio for approximately $4.1 billion, adding radiopharmaceutical therapeutics (RPTs) to its pipeline. Chris Boerner, Chief Executive Officer, Bristol Myers Squibb, said: “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s growth in the back half of the decade and beyond.

article thumbnail

Morgan Stanley Supercharged Its Customer Journey. Learn How at Adobe Summit 2024!

Perficient: Drug Development

Adobe Summit 2024 is right around the corner, and we’re excited to sit down with the executive director of marketing applications at Morgan Stanley Dorothy Joseph on March 27 at 11:30 A.M PST at The Grand Lux Café in The Palazzo. Perficient’s Jay Jackson, director of Adobe Digital Marketing and CDP, will host a fireside chat with Joseph about the global financial services leader’s successful journey to consolidate and optimize the Adobe Experience Platform.

Marketing 109
article thumbnail

What Is Measles, and How Can I Shield Myself & My Family?

Drugs.com

WEDNESDAY, Feb. 28, 2024 -- Once thought to be a bygone disease, measles is making a comeback in the United States and globally as folks shun a safe, surefire way to prevent it: The measles vaccine. But what is measles, and how easily does it.

Vaccine 111
article thumbnail

Obesity drug from Boehringer, Zealand succeeds in MASH trial

BioPharma Drive: Drug Pricing

Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

Trials 115
article thumbnail

FDA withdraws approval of Oncopeptides’ Pepaxto

Drug Discovery World

The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval was withdrawn as the confirmatory study conducted as a condition of accelerated approval did not confirm Pepaxto’s clinical benefit, and Pepaxto has not been proved to be safe or effective u

FDA 130
article thumbnail

The future of cancer immunotherapy with Elicio Therapeutics

Drug Target Review

Can you elaborate on the key findings of the preclinical data published in Cancer Immunology Research? How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? In this study , we demonstrated that AMP immunotherapy can boost TCR-T cell therapy by acting directly in the lymph nodes to promote the coordination of tumour-specific T cell responses by antigen presenting cells.

article thumbnail

Is It Allergies or Sinusitis? Many Folks Are Misdiagnosed

Drugs.com

WEDNESDAY, Feb. 28, 2024 -- What if you'd been treated for years for a condition, only to find out that you'd long ago been misdiagnosed?That's what's happening to a sizable number of Americans who are taking allergy meds (to little effect) when in.

109
109
article thumbnail

Gritstone to lay off 40% of workforce after costly study delay

BioPharma Drive: Drug Pricing

The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized vaccine for cancer.

Vaccine 119
article thumbnail

Positive top-line results for dual GLP-1/GIP receptor agonist in obesity

Drug Discovery World

Viking Therapeutics has reported positive top-line results from the Phase II VENTURE trial of VK2735 in patients with obesity. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The study demonstrated statistically significant reductions in body weight at all doses as compared to placebo, up to 13.1% placebo-adjusted mean weight loss.

Trials 130
article thumbnail

New study links placental oxygen levels to fetal brain development

Science Daily: Pharmacology News

A new study shows oxygenation levels in the placenta, formed during the last three months of fetal development, are an important predictor of cortical growth (development of the outermost layer of the brain or cerebral cortex) and is likely a predictor of childhood cognition and behavior.

105
105
article thumbnail

Service Dogs May Lessen Seizure Frequency in Folks With Epilepsy

Drugs.com

THURSDAY, Feb. 29, 2024 -- Perhaps by reducing anxiety, a service dog can help reduce seizures in people with tough-to-treat epilepsy, a new study finds.A group of 25 study participants had an average 31% fewer seizures after months of owning a.

109
109